DUBLIN--(BUSINESS WIRE)--The "Gastroesophageal (GE) Junction Carcinomas Ongoing Global Clinical Trials Analysis and Outlook" report has been added to ResearchAndMarkets.com's offering.

Testing Molecular Therapies in Hepatocellular Carcinoma: The Need for Randomized Phase II Trials One questions, therefore, whether the “lumping” of these diseases in clinical trials only muddies what ...

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Gastroesophageal (GE) Junction Carcinomas - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. The ...

For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) yields better event-free survival outcomes ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Nivolumab monotherapy was well tolerated and showed antitumor activity in patients with advanced ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Among patients with previously treated HER-2–positive locally advanced or metastatic gastric or ...